title: [Approaches to raising efficacy of treatment of patients with chronic prostatitis associated with intracellular infections].
abstract: The efficacy of indigal plus containing indol-3-carbinol, epigallocatexin-3-gallat and Serenoa repens extract in combination with sparfloxacin was studied in a trial with participation of 30 patients with chronic infectious prostatitis associated with intracellular agents. Group 1 (n=15) received indigal plus (2 capsules twice a day for 3 months) and sparfloxacin (200 mg twice a day for 1 month). Group 2 including 15 matched controls received sparfloxacin alone according to the same schedule. The examination included questionnaire survey (IPSS, QoL, NIH-CPSI), blood count, urinalysis, PSA test, microscopy, bacteriological study of prostatic secretion, uroflowmetry, transrectal ultrasound investigation of the prostate with residual urine assay, laser doppleroflowmetry. The examinations were performed on the treatment day 30, 60 and 90. After the antibacterial treatment chlamidia, ureaplasma and E.coli were detected in 13.3, 6.7 and 26.7% patients of the control group, in 6.7, 6.7 and 6.7% patients of the study group, respectively. Thus, the addition of a pathogenetic drug indigal plus to sparfloxacin treatment promoted normalization of apoptosis of the infected cells, led to more effective bacterial eradication, enhanced regression of the symptoms. It is recommended to include indigal plus in a basic scheme of treatment of patients with chronic infectious prostatitis.
authors.forename: E V
authors.initials: EV
authors.lastname: Kul'chavenia
authors.forename: A A
authors.initials: AA
authors.lastname: Breusov
authors.forename: E V
authors.initials: EV
authors.lastname: Brizhatiuk
authors.forename: D P
authors.initials: DP
authors.lastname: Kholtobin
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D002392:Catechin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002908:Chronic Disease; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000627:therapeutic use; D011467:Prostate / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology; D011472:Prostatitis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D015231:Sexually Transmitted Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014463:Ultrasonography; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D024841:Fluoroquinolones; D007211:Indoles; D010936:Plant Extracts; C012381:indole-3-carbaldehyde; D002392:Catechin; C045651:epigallocatechin gallate; C061363:sparfloxacin